|
Presented By:
Supported by an educational grant from Gilead Sciences
System Requirements
The following are required to view these programs:
Windows
- Windows 2000, ME, XP,
or Vista
- IE5 or later/NetScape 7/Mozilla 1.5/Opera 7/Firefox
Macintosh
- OS X or later
- Safari/Mozilla 1.5
All
- Flash Player 9
- Broadband (Cable/DSL or higher)
|
Please read below and scroll to bottom to launch program.
Program Overview:
Chronic hepatitis B (CHB) afflicts 350 million persons worldwide and an estimated 1.25 million individuals in the US. The health and well-being of these patients depends upon their clinician being knowledgeable regarding the significant advances in the diagnosis and treatment of CHB that have occurred in the past five years. The wide range of clinical manifestations of CHB and the availability of multiple treatment options for CHB significantly increase the importance of clinician education regarding (1) the natural history and epidemiology of CHB, including the effects of genetic diversity of HBV on its natural history, (2) effective strategies for treatment of CHB, including the potential limitations of treatment, for example, the inability to eradicate HBV and the potential for emergence of HBV resistance, and (3) appropriate monitoring strategies for the prevention and early detection of HBV-related complications. This program is designed to provide clinically-relevant education on these and other CHB-related topics in a novel and effective presidential-debate style format which will feature two nationally known and recognized CHB experts.
This tuition-free program is for health care providers who treat CHB patients and there are no prerequisites. |
|
Learning Objectives and Program Details:
After participating in this activity, the participants should be able to:
|
|
•
|
Summarize, discuss with colleagues, and apply clinically the most recent and relevant data on the diagnosis, management and treatment of CHB including the use of new diagnostic and monitoring tools and recently approved therapies;
|
|
•
|
Assess CHB patients and make an appropriate clinical decision regarding the role of and need for liver biopsy;
|
|
•
|
Review patient case scenarios and be able to outline and discuss the factors to consider when deciding on when to start CHB therapy;
|
|
•
|
Be aware of and knowledgeable about the risks and benefits of various CHB therapies currently available;
|
|
•
|
Assess and explain the potential role of combination therapy in treatment-naïve and treatment-experienced patients; and
|
|
•
|
Evaluate the potential role for HBV resistance testing and the potential for resistance associated with various CHB treatment strategies in the context of clinical case scenarios.
|
The Johns Hopkins University School of Medicine takes responsibility for the
content, quality, and scientific integrity of the CME activity.
Accreditation Statement:
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement:
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Release Date: August 5, 2009 / Expiration Date: August 4, 2010
Course Directors:
Douglas T. Dieterich, MD
Professor of Medicine and Director of CME,
Department of Medicine,
Director of Outpatient Hepatology,
Division of Liver Diseases,
Mount Sinai School of Medicine
Mark Sulkowski, MD,
Associate Professor of Medicine and Medical Director,
Viral Hepatitis Center,
Johns Hopkins University School of Medicine
Full Disclosure Policy Affecting CME Activities:
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Johns Hopkins University School of Medicine to require the disclosure of the existence of any relevant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following.
Dr. Douglas T. Dieterich:
- Sources of Funding for Research:None
- Consulting/Honorarium Agreements: Roche, Tibotec, BMS, Gilead Sciences
- Speakers' Bureau: Roche, Tibotec, BMS, Gilead Sciences, GSK
- Financial Interests/Stock Ownership: None
Dr. Mark Sulkowski:
- Sources of Funding for Research: Roche, Schering-Plough, Vertex, Merck, Gilead Sciences, Human Genome Sciences, Idenix, Mederax, Tibotec, Debiopharm
- Consulting Agreements: Roche, Schering, Vertex, Merck, HGS, Tibotec, Pfizer, BMS
- Speakers' Bureau/Honorarium Agreements: None
- Financial Interests/Stock Ownership:None
Dr. Albert Min:
- Sources of Funding for Research: Bristol Myers-Squibb, Gilead Sciences
- Consulting/Honorarium Agreements: Bristol Myers-Squibb, Gilead Sciences
- Speakers' Bureau: Bristol Myers-Squibb, Gilead Sciences
Notice of Unlabeled/Unapproved Uses:
Dr. Dieterich, Dr. Sulkowski, and Dr. Min have disclosed that their presentation will reference unlabeled/unapproved use of information on studies and data presented on off-label uses of entecavir, tenofovir, adefovir, interferon, and lamivudine.
Method to Participate:
To participate in this tuition-free CME program, link to the website, review the material and complete the post-test evaluation to receive your CME certificate.
Request for Program Slides and Review:
To request a copy of the program slides as well as further education on how to use the slides please Click Here to fill out a content request form.
Opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME program. CME collects only the information necessary to provide you with the services that you request.
Copyright © 2008 The Johns Hopkins University School of Medicine. All rights reserved.
|
